Achieve Life Sciences (ACHV) Current Deferred Revenue (2010 - 2016)

Achieve Life Sciences has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $2.1 million for Q1 2016.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $2.1 million in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $2.1 million (changed N/A YoY) and the FY2015 annual result came in at $5.0 million, changed N/A from the prior year.
• Current Deferred Revenue slipped to $2.1 million in Q1 2016, from $5.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $17.8 million in Q2 2015 and troughed at $2.1 million in Q1 2016.
• A 3-year average of $11.1 million and a median of $11.0 million in 2015 frame the typical range for Current Deferred Revenue.
• Biggest YoY gain for Current Deferred Revenue was 53.72% in 2012; the steepest drop was 8.55% in 2012.
• Tracing ACHV's Current Deferred Revenue over 3 years: stood at $9.1 million in 2012, then slumped by 44.89% to $5.0 million in 2015, then plunged by 58.35% to $2.1 million in 2016.
• Business Quant data shows ACHV's Current Deferred Revenue at $2.1 million in Q1 2016, $5.0 million in Q4 2015, and $11.0 million in Q3 2015.